Evogene and Tel Aviv University launch drug discovery initiative

Evogene and Tel Aviv University’s BCDD have partnered to expedite small-molecule drug discovery originating from Israeli academic research. The partnership will connect Evogene’s AI-based ChemPass AI with the BCDD’s laboratory infrastructure. The initiative seeks to address obstacles by making resources of both entities available to selected ventures. Credit: Gorodenkoff / Shutterstock.com. Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating from Israeli academic research. Facilitated by Ramot, which manages technology transfer for Tel Aviv University, the agreement will combine computational and experimental tools…

Source: Pharmaceutical Technology